OnKure Therapeutics, Inc. (OKUR) Earnings History
Net Loss6 years of earnings data (2020–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
OnKure Therapeutics, Inc. (OKUR) Earnings Overview
As of July 8, 2026, OnKure Therapeutics, Inc. (OKUR) reported trailing twelve-month net income of -$44M, reflecting -11.4% year-over-year growth. The company earned $-3.19 per diluted share over the past four quarters.
Looking at the long-term picture, OKUR's historical earnings data spans multiple years. The company achieved its highest annual net income of -$19M in fiscal 2020.
OnKure Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including KYMR (-$315M net income, -794.4% margin), ARVN (-$221M net income, -30.8% margin), PRAX (-$327M net income), OKUR has comparable earnings metrics. Compare OKUR vs KYMR →
OKUR Earnings vs Peers
Earnings metrics vs comparable public companies
OKUR Historical Earnings Data (2020–2025)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$60M | -13.0% | -$63M | $-4.40 | - | - |
| 2024 | -$53M | -49.2% | -$54M | $-3.95 | - | - |
| 2023 | -$35M | -19.6% | -$37M | $-2.65 | - | - |
| 2022 | -$30M | +25.8% | -$30M | $-2.21 | - | - |
| 2021 | -$40M | -104.3% | -$40M | $-21.92 | - | - |
| 2020 | -$19M | - | -$20M | $-7.74 | - | - |
Download Data
Export OKUR earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
OKUR — Frequently Asked Questions
Quick answers to the most common questions about buying OKUR stock.
What is OKUR earnings per share (EPS)?
OKUR trailing twelve-month (TTM) diluted EPS is $-3.19, reflecting -11.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2020 to 2025 is available in the table on this page.
What is OnKure Therapeutics, Inc.'s net income?
OnKure Therapeutics, Inc. (OKUR) trailing twelve-month net income is $-44M as of 2025. Earnings declined -11.4% year-over-year.
Is OKUR profitable?
OKUR is not currently profitable on a TTM basis, reporting a net loss of $-44M. Net margin is N/A. Investors should monitor for a return to profitability.
What is OKUR's earnings growth rate?
OKUR compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2020 to 2025.
What are OKUR's profit margins?
OnKure Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -74.4%.
Is OKUR growing earnings?
OKUR earnings are declining — EPS fell -11.4% year-over-year. TTM net income dropped to $-44M. This contrasts with the 5-year CAGR of N/A.
What was OKUR's best earnings year?
OnKure Therapeutics, Inc.'s highest annual net income on record is $-19M, achieved in fiscal year 2020. Earnings history on this page spans 2020 to 2025 and includes all annual and quarterly figures.
What were OKUR's earnings last quarter?
OKUR's most recent reported quarter was Q1 2026. Net income was $0.00 with diluted EPS of $-1.11. For a full breakdown of all quarters, see the quarterly earnings table on this page.